Project Code
Target
Indicant
MOA & Molecule Type
Phase 3
Phase 2
Phase 1
Preclinical
Peptide Receptor Radionuclide Therapy
Renal cancer
CAIX
Late
Discovery
Peptide Receptor Radionuclide Therapy
(Pro-Drug)
Neuroendocrine tumor
SSTR2
PRRT, PDC, Pro-drug
solid cancer
FAP
CNP
Achondrogenesis
NPR-B
Pipeline
CBT-005
Early
Discovery
Target: NPR-B
Indicant: Achondrogenesis
MOA & Molecule Type: Peptide CNP
Development stage: R&D
Summary: Achondrogenesis is a disease that causes problems in bone growth of cartilage and is caused by mutations in the FGFR3 gene and failure to produce proper bones.
In order to prevent the proliferation and differentiation of cartilage cells from being inhibited, CNP (C-type natural peptide) must activate NPR-B in cartilage to suppress the activity of RFP, an intermediate product in the FGFR3 signaling process.
Currently, the product approved as a treatment is Voxzogo one substance and has been approved as a "rare drug." Our company compared to existing treatments, the company has increased stability in the body by using D-amino acid and is developing treatments that are cartilage-specific and strong binding to NPR-B through material advancement.